Divvying Up The Stem Cell Bonanza
By Business Week,
Business Week
| 11. 22. 2004
California's Proposition 71 has critics of conflicts and favoritism ready to pounce
Long before California voters passed Proposition 71 on Nov. 2, authorizing the state to pour $3 billion of taxpayers' money into stem cell research, the measure generated plenty of debate. And it wasn't just conservatives opposing the measure on religious grounds. Even supporters of the research, which one day could lead to cures for everything from diabetes to cancer, argued that the law gives vested interests too much say over who will get the funds.
So as officials move to appoint an oversight committee that will weigh funding requests, they are mindful that critics will be watching their every move. While architects of the law insist the appropriate checks and balances are built in, controversy continues to swirl around a decision-making process that some see as overly secretive. "Clearly the initiative is written to invite every conceivable form of corruption in the allocation of these funds," says Republican State Senator Tom McClintock, who opposed the law.
The controversy in California is broadly echoed at the federal level. Over...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...